Cargando…
Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc
Dysregulated cholesterol metabolism is a hallmark of colorectal cancer (CRC). However, the usage of cholesterol-lowering agents seemed to have no benefit in CRC patients. In this study, we focused on the cholesterol-nuclear receptors (NRs) axis as a strategy. Cholesterol and its derivatives work as...
Autores principales: | Wang, Ying-Nan, Ruan, Dan-Yun, Wang, Zi-Xian, Yu, Kai, Rong, Dai-Lin, Liu, Ze-Xian, Wang, Feng, Hu, Jia-Jia, Jin, Ying, Wu, Qi-Nian, Pu, Heng-Ying, Wang, Min, Xu, Rui-Hua, Zeng, Zhao-Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718673/ https://www.ncbi.nlm.nih.gov/pubmed/36316442 http://dx.doi.org/10.1038/s41388-022-02515-3 |
Ejemplares similares
-
The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis
por: Ruan, Qingguo, et al.
Publicado: (2011) -
Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019) -
RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype
por: Cai, Demin, et al.
Publicado: (2019) -
The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT
por: Karaś, Kaja, et al.
Publicado: (2019) -
The application of machine learning methods to the prediction of novel ligands for RORγ/RORγT receptors
por: Bachorz, Rafał A., et al.
Publicado: (2023)